What are the current treatment guidelines for squamous non‑small‑cell lung cancer in an adult patient with untreated metastatic disease and ECOG performance status 0‑1?

Treatment Guidelines for Squamous Cell Lung Cancer (Metastatic, ECOG PS 0-1)

For adults with untreated metastatic squamous non-small-cell lung cancer and good performance status (ECOG 0-1), pembrolizumab combined with carboplatin and paclitaxel (or nab-paclitaxel) is the standard first-line treatment, provided there are no contraindications to immunotherapy. 1

First-Line Treatment Algorithm

Step 1: Assess Immunotherapy Eligibility

• If no contraindications to immunotherapy exist: Proceed with chemoimmunotherapy as the preferred approach 1
• If contraindications to immunotherapy are present: Use platinum-based chemotherapy doublet alone 1

Step 2: Select First-Line Regimen Based on Immunotherapy Eligibility

Preferred Option (No Immunotherapy Contraindications):

• Pembrolizumab + carboplatin + paclitaxel or nab-paclitaxel (100% consensus, Level I evidence) 1
  • This combination is considered the standard choice for metastatic squamous NSCLC with PS 0-1 1
  • Survival benefit observed across all PD-L1 expression levels 1

Alternative Immunotherapy-Based Option:

• Atezolizumab + carboplatin + nab-paclitaxel (83% consensus, Level I evidence) 1
  • Represents another option for PS 0-1 patients without immunotherapy contraindications 1

If High Tumor Mutational Burden (TMB):

• Nivolumab + ipilimumab (83% consensus, Level I evidence) 1
  • Treatment option for PS 0-1 patients with high TMB, regardless of PD-L1 expression 1

Step 3: Chemotherapy-Only Regimens (If Immunotherapy Contraindicated)

Platinum-based doublets with third-generation cytotoxic agents are recommended (100% consensus, Level I evidence) 1:

• Carboplatin + gemcitabine 1
• Carboplatin + paclitaxel 1
• Carboplatin + vinorelbine 1
• Cisplatin-based doublets may be used with same agents 1

Nab-paclitaxel regimen is an alternative, particularly for patients with neurotoxicity risk or paclitaxel hypersensitivity (100% consensus, Level I evidence) 1

Step 4: Treatment Duration and Maintenance

• Administer 4 cycles of platinum-based doublet followed by less toxic maintenance monotherapy 1
• Maximum of 6 cycles if patient not suitable for maintenance 1
• Continuation maintenance with gemcitabine is an option after cisplatin-gemcitabine (100% consensus, Level I evidence) 1
• Maintenance decisions should consider response, remaining toxicity, PS, and patient preference 1

Additional Considerations

Necitumumab Option:

• Necitumumab + gemcitabine + cisplatin represents a treatment option for advanced squamous NSCLC expressing EGFR by immunohistochemistry (83% consensus, Level II evidence) 1

Critical Exclusions for Squamous Histology:

• Pemetrexed is restricted to non-squamous NSCLC only (100% consensus, Level I evidence) 1
• Bevacizumab is contraindicated in squamous histology due to safety concerns (hemorrhage risk) 1, 2

Smoking Cessation:

• Strongly encourage smoking cessation at any stage, as it improves outcomes (100% consensus, Level II evidence) 1

Common Pitfalls to Avoid

1. Do not use pemetrexed in squamous NSCLC—it is only for non-squamous histology 1
2. Do not use bevacizumab in squamous NSCLC due to bleeding risk 1, 2
3. Do not delay treatment while awaiting extensive molecular testing—squamous NSCLC has low prevalence of actionable mutations 3
4. Do not use single-agent immunotherapy as first-line unless patient cannot tolerate chemotherapy—combination therapy provides superior outcomes 1
5. Be aware of ICI half-life if switching from immunotherapy to other treatments due to potential adverse events 1

Second-Line Treatment Options

After progression on first-line therapy with PS 0-2, second-line therapy should be offered (100% consensus, Level I evidence) 1:

• Docetaxel (Level I evidence) 1
• Ramucirumab + docetaxel (Level I evidence) 1
• Nintedanib + docetaxel (Level II evidence) 1
• Single-agent chemotherapy options: gemcitabine, vinorelbine, or docetaxel 1